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Abstract
Objective—To review the effects of vitamin D supplementation on depression or depressive
symptoms in randomized controlled trials. Although low vitamin D levels have been
observationally associated with depression and depressive symptoms, the effect of vitamin D
supplementation as an antidepressant remains uncertain.
METHODS—MEDLINE, CINAHL, Allied and Complimentary Medicine Database, PsycINFO,
Scopus, and The Cochrane Library, and references of included reports (through May 2013) were
searched. Two independent reviewers identified randomized trials that compared the effect of
vitamin D supplementation on depression or depressive symptoms to a control condition. Two
additional reviewers independently reviewed and extracted relevant data; disagreements were
reconciled by consensus. The Cochrane Risk of Bias Tool was used to assess study quality. Seven
trials (3191 participants) were included.
RESULTS—Vitamin D supplementation had no overall effect on depressive symptoms
(standardized mean difference [SMD], −0.14; 95% CI, −0.33 to 0.05; P = 0.16), although
considerable heterogeneity was observed. Subgroup analysis showed that vitamin D
supplementation for participants with clinically significant depressive symptoms or depressive
disorder had a moderate, statistically significant effect (2 studies: SMD, −0.60; 95% CI, −1.19 to
−0.01; P = 0.046), but a small, nonsignificant effect for those without clinically significant
depression (5 studies: SMD, −0.04; CI, −0.20 to 0.12; P = 0.61). Most trials had unclear or high
risk of bias. Studies varied in the amount, frequency, duration, and mode of delivery of vitamin D
supplementation.
Conclusion—Vitamin D supplementation may be effective for reducing depressive symptoms in
patients with clinically significant depression; however, further high quality research is needed.
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Depression is a highly prevalent and debilitating chronic illness that can be difficult to treat
(1, 2), and both depressive disorders and subthreshold depressive symptoms are associated
with significant disability, mortality, and health care costs (3, 4). Although the underlying
pathophysiology of depression remains unknown and probably involves several
mechanisms, a possible role of vitamin D in depression has received considerable attention
(5). Indeed, a recent systematic review and meta-analysis (6) of case-control, cross-
sectional, and prospective observational cohort studies of depression and vitamin D
provided some support for an association of depression with low concentrations of serum
25-hydroxyvitamin D (25[OH]D), the primary circulating form of vitamin D that is used to
determine a patient's vitamin D status (7). Although these findings are compelling, the most
important questions concerning the association of vitamin D with depression are (1) is the
association causal, and (2) does vitamin D supplementation affect depressive symptom
level?
We conducted a systematic review and meta-analysis of randomized controlled trials to
investigate whether vitamin D supplementation improves -- or potentially worsens--
depressive disorder or depressive symptoms. On the basis of previous narrative reviews (8,
9), we hypothesized that vitamin D supplementation would have a minimal effect on
depression in these trials.
Methods
We followed the Cochrane Handbook for Systematic Reviews to plan and conduct this meta-
analysis (10), and we report our findings according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines (11).
Data Sources and Searches
We systematically identified all randomized controlled trials that examined the effect of
vitamin D supplementation on depressive disorder or depressive symptoms. Although it is
difficult to detect treatment effects in those with few, if any, baseline depressive symptoms
(12), we nonetheless included studies of both nondepressed and depressed individuals
because of our interest in determining whether vitamin D supplementation either worsened
or improved depression. Potentially relevant articles were identified by searching the
biomedical electronic databases Ovid MEDLINE, The Cochrane Library, Cumulative Index
to Nursing and Allied Health Literature, Allied and Complimentary Medicine Database,
PsycINFO, and Scopus. Dates were searched from inception to the second week of May
2013. Registers of clinical trials were searched for unpublished and ongoing studies. The
initial search was conducted on June 1, 2012, and weekly searches were conducted
thereafter through May 15, 2013. All relevant subject headings and free-text terms were
used to represent vitamin D and depression. Additional records were identified by searching
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the reference lists of relevant studies and reviews and by using the Related Articles feature
in PubMed and the Cited Reference Search in ISI Web of Science. The search did not have
any language or year restrictions, and we considered all studies regardless of their
publication status. The exact search terms and search strategies for each database are
reported in Table S1 in Supplemental Digital Content 1.
To determine the studies to be included in the meta-analysis, 2 trained reviewers (N.E., P.L.)
independently read the title and/or abstract of every record retrieved. All potentially relevant
articles were investigated as full text, and differences in opinion between the 2 reviewers
were resolved by consensus or in consultation with one of the authors (J.A.S.).
Database Extraction and Quality Assessment
Two additional reviewers (L.F., K.H.) worked independently of each other and in
consultation with the first author to extract relevant data from each report. These data
included study characteristics (setting, design, randomization, masking, intent-to-treat
analyses, sample size, trial entry criteria related to depression and vitamin D, and primary
depression measure), participant demographic characteristics (age and sex), and clinical
characteristics (baseline concentration of 25[OH]D and depression status). Additional data
were extracted to characterize the type, amount, frequency, duration, and mode of delivery
of vitamin D supplementation, type of control conditions, and trial requirements regarding
the use of nonstudy vitamin D supplementation. Study quality was assessed using the
Cochrane Risk of Bias Tool (13), which considers the reporting and adequacy of random
sequence generation, randomization concealment, masking of participants, research
personnel, and outcome assessors, and methods for dealing with participants who were lost
to follow-up or had missing data for other reasons.
Data on mean (SD) depressive symptoms were extracted as the primary end point given that
no studies included a diagnosis of depressive disorder as an end point. We used available
data to calculate change-from-baseline differences within and between treatments. Change
scores were standardized using the SD of change. Two studies (14, 15) reported results as
mean (SD) preintervention and postintervention depressive symptom scores but did not
provide estimates of the pre-post correlation of depression scores that are required to
compute effect sizes. We attempted to contact study authors to request these additional data
but ultimately estimated the pre-post correlation of depression scores using published data
(16, 17). Two studies included 2 intervention groups with different doses of vitamin D
supplementation (14, 18), and 1 study included 2 control groups (15). We pooled means and
SDs across the 2 intervention and control groups in these studies to calculate effect sizes.
Statistical Analysis
Data were entered into an electronic database and analyzed using Comprehensive Meta
Analysis (version 2.0; BioStat Software, Englewood, NJ) (19). We weighted each study's
effect size using the inverse variance method. To summarize intervention effects across
trials, we pooled data in random-effects models, which provide more conservative summary
effect estimates than fixed-effects models even in the absence of statistically significant
between-study heterogeneity (20). Data are expressed as standardized mean differences
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(SMDs) and 95% CIs for the primary end point of depressive symptoms. The magnitude of
intervention effects was characterized as small (SMD = 0.2), medium (SMD = 0.5), and
large (SMD = 0.8) according to Cohen's recommendations (21).
Between-study heterogeneity was assessed using the Cochrane Q statistic, with a
significance level set at P < .10. The magnitude of heterogeneity was evaluated using the I2
statistic, and values of 50% or greater were considered indicative of substantial
heterogeneity (10). Post hoc subgroup analyses were conducted for baseline depression
status (trials of participants with clinically significant depressive symptoms or major
depressive disorder vs trials that excluded such participants or whose participants had
baseline depressive symptom scores indicative of no or mild depression [22, 23]) and
baseline vitamin D status (insufficient vs sufficient [7]). Mixed-effects analyses, in which
random-effects models are used to combine studies within subgroups, were used to conduct
subgroup analyses, and the Q statistic was calculated to compare intervention effects among
studies.
We conducted sensitivity analyses in which we substituted a range of pre-post correlations (r
= 0.1, 0.4, 0.8, and 0.9) in depressive symptoms for the 2 studies that did not report these
data. An additional sensitivity analysis was conducted that excluded an unpublished thesis
that qualified for inclusion in our meta-analysis (15).
Although the validity of procedures for detecting publication bias is limited when the
number of studies is as small as in the current meta-analysis (24), we planned to inspect
funnel plots and compute Rosenthal's fail-safe N, which provides an estimate of the number
of missing studies with nonsignificant effects that would be needed to make a significant P
value for the observed aggregate effect nonsignificant (25). Given that we obtain a
nonsignificant overall effect, however, we did not conduct these assessments.
RESULTS
Search Results
The search for randomized controlled trials of vitamin D supplementation for depressive
disorder or depressive symptoms identified 2394 reports. Details of the study flow are
documented in Figure S1, Supplemental Digital Content 1. Of the 1829 nonduplicate articles
identified by the initial search, 1797 were deemed ineligible or irrelevant on the basis of
their titles and abstracts; the remaining 32 articles, in addition to 2 articles (18, 26) that were
identified after the completion of the initial search through weekly database searches,
required full reading. Of these 34 potentially eligible articles, 7 randomized controlled trials
(14, 15, 16, 26-29) met our criteria for inclusion. Nearly all studies that were excluded at the
full-text stage of review did not feature intervention designs; however, we excluded 3
intervention studies that did not feature randomization (30), did not include a depression
outcome measure (31), or for which no published data could be identified (32).
Trial Characteristics
Table 1 and Table 2 detail the characteristics of the 7 randomized controlled trials identified
by our search that examined the effect of vitamin D supplementation for depressive
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symptoms (total N= 3191; age range, 18-79 years) by participant and study characteristics
and depression and vitamin D trial entry criteria, respectively. All trials were published
between 2003 and 2013. Two studies required that participants have low levels of 25(OH)D
at baseline (18, 29), and participants in a third study (15) of older adults also had baseline
concentrations of 25(OH)D consistent with definitions of vitamin D deficiency (<50
nmol/L). Five trials either did not specifically recruit participants with depression (15) or
excluded those with depressive disorders, elevated depressive symptoms, and/or current
antidepressant use (14, 27 - 29). The baseline depressive symptom scores of the participants
in these 5 trials suggest that they had no depressive disorder or minimal, nonclinically
significant depressive symptoms (22, 23). The primary end point for all 7 studies was
depressive symptom scores, although the specific instruments used to assess depressive
symptoms varied.
Characteristics of the vitamin D supplementation used in each of the 7 randomized
controlled trials included in this review are reported in Table 3. All but one study (18)
specified vitamin D3 (cholecalciferol) as the type of supplement. Mode of delivery, dosage
(range, 600-300,000 IU), frequency (daily vs weekly vs one-time administration), and
duration (range, 6 weeks to 2 years) of supplementation varied between studies, as did types
of control conditions and requirements regarding the use of nonstudy vitamin D
supplementation.
Assessment of study quality with the Cochrane Risk of Bias Tool demonstrated at least one
unclear or high risk of bias in all but 2 trials (Table S2, Supplemental Digital Content 1) (28,
29). The most common types of bias pertained to randomization concealment (14, 15, 16,
26, 27) and masking of research personnel (14, 15, 18, 26, 27), which were rated as posing a
high or unclear risk in 5 of 7 trials.
Effect of Vitamin D Supplementation for Depressive Symptoms
The overall reduction in depressive symptoms associated with vitamin D supplementation
was small and nonsignificant (SMD, −0.14; 95% CI, −0.33 to 0.05; P = 0.16) (Figure).
Analyses of heterogeneity revealed substantial variation among intervention effects (Q6 =
20.2, P = 0.003, I2 = 70.3), and SMDs ranged from −0.96 (P = 0.004) in favor of vitamin D
supplementation to 0.15 (P = 0.49) in favor of control.
Subgroup analyses were conducted to identify potential sources of heterogeneity among
intervention effects (Figure). The 4 studies of participants whose baseline vitamin D status
was sufficient (>50 nmol/L) showed a larger reduction in depressive symptoms (SMD,
−0.22; 95% CI, −0.53 to 0.08; P = 0.15) than the 3 studies of participants whose baseline
vitamin D status was insufficient (SMD, −0.05; 95% CI, −0.31 to 0.20; P = 0.69); however,
the difference in intervention effects between these 2 subgroups of studies was not
significant (Q1 = 0.70, P = 0.40) and neither subgroup of studies had a statistically
significant intervention effect.
A post hoc subgroup analysis was also conducted to compare studies of participants with
clinically significant depressive symptoms and/or major depressive disorder with those that
either explicitly excluded participants with clinically significant depression or included
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participants with nonclinically significant depressive symptoms at baseline (Figure). These
analyses revealed that the effect of vitamin D supplementation on depressive symptoms was
moderate and statistically significant in the 2 studies of participants with clinically
significant depressive symptoms and/or major depressive disorder (SMD, −0.60; 95% CI,
−1.19 to −0.01; P = 0.046). In contrast, the effect of vitamin D supplementation on
depressive symptoms among trials of nonclinically depressed participants was small and not
statistically significant (SMD, −0.04; 95% CI, −0.20 to 0.12; P = 0.61). The difference in
intervention effects between these 2 subgroups approached statistical significance (Q1 =
3.22, P = 0.07). We planned to investigate further sources of heterogeneity by conducting
subgroup analyses of dose; however, the use of different amounts, frequencies, and
durations of vitamin D in each trial precluded this analysis.
Sensitivity analyses, in which a range of pre-post correlations among depressive symptom
scores were substituted for the published estimates used in the primary analyses, did not
change the statistical significance of the overall intervention effect or the analyses of
between-study heterogeneity among effects. Removal of the unpublished thesis from our
analyses also did not change the primary results.
Discussion
This systematic review and meta-analysis report is the first to examine the effect of vitamin
D supplementation on depressive symptoms. We found that vitamin D supplementation
neither worsened nor improved depressive symptoms across 7 randomized controlled trials,
but considerable heterogeneity of study characteristics and intervention effects among
studies was observed. Although baseline vitamin D status did not explain the between-study
heterogeneity in intervention effects, baseline depression status may have. Whereas vitamin
D supplementation was associated with a statistically significant, moderate reduction in
depressive symptoms across 2 trials that recruited patients with clinically significant
depressive symptoms and/or major depressive disorder, its effect in trials of participants
with nonclinically significant depression was small and nonsignificant.
Notwithstanding the biological plausibility of a causal role for vitamin D deficiency in
depression (33), the results of this review suggest that the use of vitamin D supplementation
to reduce depressive symptoms for individuals without clinicallysignificant depression may
not be warranted. Although trials of nonclinically depressed individuals differed
considerably in the type of participants they included, their study locations and designs, and
characteristics of their intervention and control conditions, 4 of these 5 trials had
nonsignificant intervention effects (15, 27-29). These null findings are not entirely
surprising given that the association of vitamin D with depressive symptoms has not clearly
been established in nondepressed individuals. Although a recently conducted meta-analysis
of observational studies of vitamin D deficiency and depression in older adults found a
moderate and statistically significant association of lower vitamin D levels with clinically
meaningful depression in cross-sectional studies, the studies included in that review had
several methodologic biases (6). In particular, cross-sectional studies cannot rule out the
possibility of reverse causation in which patients with subthreshold depressive symptoms or
depressive disorders have less exposure to sunlight and thus lower vitamin D levels (9).
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Interestingly, the same meta-analysis included 3 prospective cohort studies (34-36) that
found a statistically significant, 2-fold increased risk of developing clinically significant
depression or depressive symptoms among those with low vitamin D levels. To date,
however, no study has examined whether vitamin D supplementation offsets the risk of
incident depressive disorder or depressive episodes, and future randomized controlled trials
may thus be needed to do so.
Of note, not all trials of nonclinically depressed participants in this review featured null
intervention effects. A trial conducted by Jorde and colleagues (14), which included
participants with overweight and obesity, found a small but statistically significant reduction
in depressive symptoms with vitamin D supplementation. This trial had an unclear risk of
bias in 3 of the 6 domains of the Cochrane Risk of Bias Tool; however, its findings suggest a
possible need for additional studies that examine mechanistic aspects of the association of
vitamin D with depressive symptoms and vitamin D intervention effects in this distinct
population. These findings also hint that overweight and obesity may contribute to some of
the observed heterogeneity of effects among the studies included in this meta-analysis,
although we could not test this hypothesis given a lack of reported data on overweight and
obesity across trials.
Although our subgroup analysis of trials with vs without participants with clinically
significant depressive symptoms and/or major depressive disorder suggests a possible
explanation for the heterogeneity of intervention effects observed in overall analyses,
several characteristics other than participants’ baseline depression status differed between
the former trials and the latter ones. In particular, characteristics of the vitamin D
interventions used in all 7 trials varied, and no 2 studies featured the same dose or duration
of vitamin D supplementation. In addition, the trial in which we observed the largest effect
of vitamin D supplementation on depressive symptoms not only included participants with
major depressive disorder and elevated depressive symptoms (26) but also used vitamin D
supplementation as an adjunctive intervention to pharmacotherapy with fluoxetine. The
other trial of participants with clinically significant depression used a dose of vitamin D that
far exceeds the single, but not necessarily cumulative, doses featured in other studies (18).
Vitamin D supplementation was also administered via intramuscular injection in that trial,
whereas other trials included in this review administered supplementation via capsule or
food. The interaction between vitamin D supplementation and selective serotonin reuptake
inhibitors such as fluoxetine, the comparative efficacy of different vitamin D dose amounts,
and the implications of using alternate modes of administration of vitamin D
supplementation thus remain unknown, and require investigation in future trials.
As a parallel to the present study, it is worth examining studies evaluating the efficacy of
omega-3 supplements for depression, which resemble studies of vitamin D for depression in
several ways. As with studies of vitamin D for depression, a large proportion of omega-3
trials involve healthy participants or those with subclinical depression (37). Meta-analyses
of omega-3 for depression have pooled across these studies and those of participants with
clinical depression (37) and concluded that the efficacy of omega-3 for depression is
stronger in clinical samples than in nonclinical ones. Similar to the results of one of the
studies (26) included in this review, the effect of omega-3 on depression may also be
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stronger when used to supplement traditional antidepressants rather than as monotherapy
(38). Most importantly, meta-analyses of studies of omega-3 for depression have helped to
guide subsequent research, as we hope the current meta-analysis will likewise do.
Several limitations of the current review warrant attention. First, we identified few trials
overall, the design characteristics of each of these studies differed considerably, and all but 2
of these trials (28, 29) had at least one unclear or high risk of bias. Although the
heterogeneity among studies is indeed striking, it is not unlike the heterogeneity observed
among studies of vitamin D for other conditions (39). The overall quality of the evidence
from each trial is thus low and poses uncertainty regarding the true effect of vitamin D
supplementation on depressive symptoms. Although it is unlikely that poor methodologic
quality biased the results of trials of nondepressed participants toward the null hypothesis of
no intervention effect, it may have inflated the treatment effects observed in the 2 trials of
participants with clinically significant depression. Second, some of the decisions that we
made while conducting our review may limit the validity of our findings. Although we
drafted a protocol and planned extensively before conducting our review and analyses, we
did not register the protocol or anticipate in advance all of the analyses that we conducted. In
particular, we performed 2 post hoc subgroup analyses given that we could not conduct an a
priori analysis of whether differences in vitamin D dose contributed to potential
heterogeneity among intervention effects. Nonetheless, these post hoc analyses were
informed by reasoned clinical and empirical considerations, and we did not conduct an
excessive number of these analyses. A third limitation is that we did not consider whether
vitamin D supplementation increased levels of 25(OH)D in each trial, and it is possible that
the null effects seen in some trials reflect a failure of the intervention to improve vitamin D
status.
The small number of studies included in this review, the considerable heterogeneity among
these studies, and the unlikely possibly of detecting intervention effects among nonclinical
samples (12) may lead one to wonder whether a systematic review and meta-analysis of
vitamin D supplementation for depression at this time is premature. Given the recently
published meta-analysis of observational studies of vitamin D deficiency and depression (6),
we believe that now is precisely the time to highlight the dearth of evidence for a causal role
of vitamin D in relation to depression, and point to the necessary next steps to determine
whether any clinical benefit is likely to be gained by vitamin D supplementation.
Notwithstanding these limitations and considerations, this systematic review and meta-
analysis report represents a timely contribution to the emerging literature on vitamin D and
depression that may inform the development of future clinical trials. Although we found a
nonsignificant effect on depressive symptoms associated with vitamin D supplementation,
the intervention effects across the 7 randomized controlled trials included in this review
varied significantly and considerably. We observed suggestive evidence that vitamin D
supplementation may be effective for participants with major depressive disorder or
subthreshold, clinically significant depressive symptoms but not for those without; however,
other potential sources of the between-study heterogeneity of intervention effects such as
obesity exist.
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We still have limited data to conclusively address whether vitamin D supplementation is
effective as either a unique drug or an adjuvant to pharmacotherapy for the treatment of
depression. Future trials are needed that not only target depressed patients but also consider
baseline levels of vitamin D (40) and how vitamin D dosing and mode of delivery may
contribute to its effects on depressive symptoms. We found no evidence of prior dosing
studies for vitamin D supplementation in patients with depression, and it may be time to
determine the optimal dose before testing such a dose against placebo in a double-blind trial.
Adding vitamin D supplementation to the armamentarium of remedies for depression,
although tempting, appears premature based on the evidence that has accumulated on this
topic thus far.
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Forest plots of randomized controlled trials investigating the effect of vitamin D supplementation on depressive symptoms,
overall and by depression and vitamin D status. Five weighted pooled intervention effect estimates (diamonds) are shown: one
for the full set of 7 trials (overall) and one each for nondepressed participants, depressed participants, participants with sufficient
vitamin D, and participants with insufficient vitamin D. Data are expressed as standardized mean differences with 95% CI, using
the inverse-variance method and random-effects models. Trials categorized as “nondepressed” did not specifically recruit
participants with depression or included participants whose baseline depressive symptom scores were indicative of no or mild
depression; trials categorized as “depressed” included participants with clinically significant depressive symptoms and/or major
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depressive disorder. Categorization of trials as “sufficient vitamin D” or “insufficient vitamin D” was based on participants’
baseline concentrations of 25-hydroxyvitamin D and established cutpoints for interpreting these concentrations (7).
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